NDC 63459-920-53 - GRANIX
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63459-920
- Requested NDC
- 63459-920-53
- Package NDCs from labels
- 63459-920-53, 63459-920-59
- Manufacturer
- Cephalon, LLC
- Effective date
- 2023-11-30
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| GRANIX - Cephalon, LLC | Cephalon, LLC | 2023-11-30 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63459-920-53 | GRANIX | 1.6 mL in 1 VIAL | INJECTION, SOLUTION | 1.6 | 26 | |
| 63459-920-59 | GRANIX | 10 in 1 CARTON | INJECTION, SOLUTION | 10 | 26 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63459-920-53 | ML - Milliliter | 63459-920 | dd698725-4fc8-4417-a676-5804bb9cc156 | 1 | 2018-12-13 |
| 63459-920-59 | ML - Milliliter | 63459-920 | d3d09eba-bcaa-4ae8-96ae-2948d4b75750 | 1 | 2018-12-13 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| FILGRASTIM | ACTIVE INGREDIENT | PVI5M0M1GW | GRANIX (TBO-FILGRASTIM) INJECTION, SOLUTION [CEPHALON, INC.] | 4 | |
| FILGRASTIM | ACTIVE MOIETY | PVI5M0M1GW | GRANIX (TBO-FILGRASTIM) INJECTION, SOLUTION [CEPHALON, INC.] | 4 | |
| ACETIC ACID | INACTIVE INGREDIENT | Q40Q9N063P | GRANIX (TBO-FILGRASTIM) INJECTION, SOLUTION [CEPHALON, INC.] | 4 | |
| POLYSORBATE 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | GRANIX (TBO-FILGRASTIM) INJECTION, SOLUTION [CEPHALON, INC.] | 4 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | GRANIX (TBO-FILGRASTIM) INJECTION, SOLUTION [CEPHALON, INC.] | 4 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | GRANIX (TBO-FILGRASTIM) INJECTION, SOLUTION [CEPHALON, INC.] | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | GRANIX (TBO-FILGRASTIM) INJECTION, SOLUTION [CEPHALON, INC.] | 4 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| hydrocortisone and acetic acid | HYDROCORTISONE AND ACETIC ACID OTIC | Saptalis Pharmaceuticals, LLC | d9a3597c-2c9d-46cc-818b-8bb3aa5c4f32 | 2025-04-25 | Warnings, Adverse reactions | Q40Q9N063P |
| Eye Wash | WATER | CMC Group Inc. | 6158a1f5-a6bc-4a3e-9d1d-0a310d9dc561 | 2025-04-02 | Warnings | 059QF0KO0R |
| AeroWash Eyewash | EYEWASH SOLUTION | Aero Healthcare US LLC | a477de08-4301-0ee5-e053-2995a90af79d | 2025-02-26 | Warnings | 059QF0KO0R |
| Advanced Eye Relief Eye Wash | WATER SOLUTION | Bausch & Lomb Incorporated | 9caccce1-4530-441d-bf76-244edeb9dedc | 2025-02-17 | Warnings | 059QF0KO0R |
| Acetic Acid | ACETIC ACID | NuCare Pharmaceuticals,Inc. | f9b4d18b-25f3-604f-e053-6394a90a5531 | 2025-02-10 | Warnings, Adverse reactions | Q40Q9N063P |
| Eyesaline Eyewash Concentrate | PURIFIED WATER | Honeywell Safety Products, Inc. | 2d90c8e8-f479-3535-e063-6394a90af122 | 2025-02-07 | Warnings | 059QF0KO0R |
| Endopan HP | ACETICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, BRYONIA (ALBA), CHROMIUM, COLCHICUM AUTUMNALE, LACTICUM ACIDUM, LYCOPODIUM CLAVATUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, SULPHUR, SYZYGIUM JAMBOLANUM, THUJA OCCIDENTALIS, URANIUM NITRICUM | Energique, Inc. | 2bc69a24-c24c-4d12-92bb-7c073edf90dc | 2025-01-24 | Warnings | Q40Q9N063P |
| Medics Choice Soothing Eye Wash | PURIFIED WATER | KC Pharmaceuticals, Inc. | 10e49808-161e-f4ec-e063-6294a90a1775 | 2025-01-19 | Warnings | 059QF0KO0R |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a2b9456-8ca0-8253-e053-2a95a90a8f12 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a2a34f9-ed95-9921-e053-2995a90a0d59 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a2bc45d-e0c8-3af2-e053-2a95a90af0f1 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a67169d-6b15-3406-e053-2995a90a60e4 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a673225-27be-040a-e053-2a95a90a0a98 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a66b61d-82bd-2bbb-e053-2995a90a0b58 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a677063-09d2-8052-e053-2a95a90affae | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a678fac-289c-0f5c-e053-2995a90a0f43 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a66da0b-ee7b-2b69-e053-2995a90ae951 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a667d80-d05c-2d18-e053-2995a90a2918 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a66e2a9-a661-e847-e053-2a95a90aa304 | 2025-01-09 | Q40Q9N063P | |
| Acidum Aceticum | ACIDUM ACETICUM | Hahnemann Laboratories, Inc. | 9a67a0bb-6943-2f5f-e053-2a95a90aac6e | 2025-01-09 | Q40Q9N063P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.